Reports, Presentations, and Articles

Reports and Plans

• Using Recency Assays for HIV Surveillance: 2022 Technical Guidance Shelley Facente provided scientific input and Facente Consulting coordinated the technical team that developed this international guidance for UNAIDS and the World Health Organization, released in December 2022, to guide country programs in using HIV recency assays (tests that discriminate recent from longstanding HIV infection) to help them better understand their HIV epidemic.
• Ending the Epidemics: Addressing Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), and Sexually Transmitted Infections (STIs) in California This strategic plan was developed during 2021 with input from a workgroup composed of diverse voices from staff of the California Department of Public Health, key stakeholders, and people with lived experience of HIV, HCV, and/or STIs. The document provides a high-level overview of the strategies for the state’s work over the next five years to end the syndemic of HIV, HCV, and STIs in California, in partnership with people at regional and local levels. The plan uses a social determinants of health framework, and centers equity and racial justice as a core part of the mission. Phase 2 of this project will be to work with stakeholders throughout the state in 2022 to create a blueprint document that turns these high-level strategies into concrete, realistic activities that will help realize the plan’s goals.
• COVID-19 vaccination fact sheet (August 3, 2021) This scientifically accurate and well-cited guide to COVID-19 vaccination is written in lay language, and was developed for a client to distribute to vaccine hesitant staff in their workplace once the Delta variant began to spread in the United States.
• Hamilton Families Strategic Plan 2021-2024 Facente Consulting worked with Hamilton Families throughout early 2021 to develop a strategic plan that would highlight their efforts to help homeless families in the Bay Area recover from the impacts of the COVID-19 pandemic, and thrive together with a safe and stable place to live.
• Ending the HIV Epidemic: California Consortium Developed for CDC on behalf of the California Department of Public Health and health department staff of Alameda, Orange, Riverside, Sacramento, San Bernardino, and San Diego counties, in response to CDC PS 19-1906, calling for five-year plans to end the HIV epidemic in high-impact jurisdictions.
• Ending the Epidemics: Collective Strategies for Addressing HIV, Hepatitis C, and Sexually Transmitted Infections in San Francisco This plan was written by Facente Consulting over a one-year period, with the input of stakeholders from the San Francisco Department of Public Health, local community organizations, and, most importantly, members of communities highly impacted by these epidemics in San Francisco.
• End Hep C SF Strategic Plan, 2020-2022 Developed for San Francisco’s collective impact initiative, End Hep C SF, to eliminate hepatitis C as a public health threat.
• Issue Brief: Addiction & Recovery This issue brief was commissioned by Battery Powered, the social engagement “giving program” within San Francisco’s social club The Battery. Issue briefs are created once per quarter to educate members on critical societal issues, to help guide foundational giving and improve their community.
• San Francisco AIDS Foundation Strategic Plan, 2019-2024 This document is the public summary of the more comprehensive strategic plan developed by Facente Consulting for the San Francisco AIDS Foundation during a year-long process.
• 2019 Community Health Needs Assessment: San Francisco Campus for Jewish Living This Community Health Needs Assessment (CHNA) was prepared by Facente Consulting as part of the tri-annual CHNA requirement for this non-profit offering residential medical services for older adults in San Francisco.
• Meeting Report: WHO Working Group on HIV Incidence Measurement and Data Use This report is a summary of the World Health Organization/UNAIDS convening of the international Working Group on HIV Incidence, held in Boston, MA in 2018. Shelley Facente served as WHO’s official rapporteur for the meeting and developed this report.
• Laying a Foundation for Getting to Zero: California’s Integrated HIV Surveillance, Prevention, and Care Plan Developed for the California Department of Public Health, this plan was released in September 2016 and has been the guiding force for the State of California’s quest to “Get to Zero” with HIV.
• Treasure Island Children and Youth Needs Assessment Prepared for the Treasure Island Homeless Development Initiative (now One Treasure Island) and the Treasure Island Development Authority (TIDA), this report provided guidance for the protection of young people already living on Treasure Island in San Francisco during its $1.6 billion redevelopment.
• Oakland Transitional Grant Area (TGA) 2015 HIV/AIDS Needs Assessment Developed for the Oakland TGA Collaborative Community Planning Council in response to three questions of focus for HIV planning in Alameda and Contra Costa Counties, CA.
• Report of an Assessment of Community Perspectives About the Protection of Vulnerable Populations During a Heat Emergency in San Francisco Developed for the San Francisco Department of Public Health, Environmental Health Branch, to help San Francisco prepare for heat emergencies as a result of global warming.

Presentations and Posters

• An Assessment of Hepatitis C Knowledge and Treatment Need in the San Francisco County Jail System Presentation to the SF-CAN Liver Cancer Task Force on behalf of End Hep C SF – Virtual – December 2022
• Comparison of HIV Incidence as Determined by Different Recency Assays in Ugandan Women HIV Glasgow – Glasgow, Scotland – October 2022
• Trends in Hepatitis C Prevalence in San Francisco: Progress Toward Elimination International Conference on Hepatitis and Health for Substance Users (INHSU) – Glasgow, Scotland – October 2022
• When Health Department Data Don’t Cut It: Strategies to Track an Epidemic International Conference on Hepatitis and Health for Substance Users (INHSU) – Glasgow, Scotland – October 2022
• Comparison of Recency Assays to Estimate HIV Incidence in the SIENA (Estimating HIV Incidence Among AGYW) Study in Uganda IDWeek – Washington, DC – October 2022
• Use of the Recent Infection Testing Algorithm to Estimate Background HIV Incidence in Micro-Epidemic Areas Within Uganda International AIDS Conference – Montreal, Canada – July 2022
• Tenant Led Approach to Overdose Prevention in Supportive Housing Health Care for the Homeless Conference – Seattle, WA – May 2022
• Time to Leave Fiebig Staging in the Dust? Estimated Dates of Detectable Infection (EDDIs) as a new and improved method for HIV infection dating. Advancing HIV, STI, and Viral Hepatitis Testing Conference – Virtual – March 2022
• Challenges and Opportunities with Interpretation of Results from Recency Assays used within HIV Testing Services Advancing HIV, STI, and Viral Hepatitis Testing Conference – Virtual – March 2022
• Hepatitis C Testing During a Global Pandemic: San Francisco’s Lessons Learned Advancing HIV, STI, and Viral Hepatitis Testing Conference – Virtual – March 2022
• Benefits of Working with a Collective Impact Initiative to Inform Research: Developing Paths to Hepatitis C Elimination for Young Adults Who Inject Drugs INHSU – Virtual – September 2021
• Context-Specific Performance of Recency Assays in South Africa and Uganda: an In Silico Simulation Approach European AIDS Conference – London, England – October 2021
• COVID-19 Data Workshop Created in partnership with Garrow Consulting, LLC, this is a self-directed presentation adapted from a data workshop commissioned by the city of Palm Springs, CA to help people better understand the flood of information out there about COVID-19.
• Association Between Public Injection and Syringe Sharing Frequency in a Cohort of People Who Inject Drugs in San Francisco and Los Angeles Meeting of the College on Problems of Drug Dependence (CPDD) – Virtual – June 2020
• Interpreting HIV Diagnostic Histories into HIV Infection Date Estimates: An Online Tool International AIDS Conference – Amsterdam, The Netherlands – July 2018
• Estimated Hepatitis C Prevalence and Key Population Sizes in San Francisco: A Foundation for Elimination 9th IAS Conference on HIV Science (HIV/HCV Co-Infection Pre-conference) – Paris, France – July 2017
• Translation Isn’t Just About Foreign Language: Bridging the Language Gap with HIV Testing CDC/APHL HIV Diagnostics Conference – Orlando, FL – March 2010

Peer-Reviewed Articles

• Funding and Delivery of Syringe Services Programs in the United States, 2022. Facente SN, Humphrey JL, Akiba C, Patel SV, Wenger LD, Tookes H, Bluthenthal RN, LaKosky P, Prohaska S, Morris T, Kral AH, and Lambdin BH. American Journal of Public Health. 2024; 114(4): 435-443.
• Let’s Connect: Impact Evaluation of an Intervention to Reduce Mental Health Disparities Among People Who are LGBTQ+. Facente SN, Davila X, Kowell N, Calma N, Kwan MM, Gupta, S. Community Mental Health Journal. 2024 (online ahead of print).
• Surviving vs. Thriving: The Challenges and Needs of Academic Medical Faculty. Kin, Cindy, Yang R, Albers A, Jimenez J, Facente SN, Girod S. The Journal of Faculty Development. 2023; 33(3): 54-61.
• Impact of HCV Testing and Treatment on HCV Transmission Among Men Who Have Sex With Men and Who Inject Drugs in San Francisco: A Modelling Analysis. Artenie A, Stone J, Facente SN, Fraser H, Hecht J, Rhodes P, McFarland W, Wilson E, Hickman M, Vickerman P, Morris MD. The Journal of Infectious Diseases. 2023 June 24 (online ahead of print).
• Monitoring SARS-CoV-2 incidence and seroconversion among university students and employees: a longitudinal cohort study in California, June–August 2020. Hunter LA, Wyman S, Packel LJ, Facente SN, Li Y, Harte A, Nicolette G, the IGI SARS-CoV-2 Testing Consortium, Di Germanio C, Busch MP, Reingold AL, Petersen ML. BMJ Open. 2023; 13:e063999.
• Using Geocoding to Identify COVID-19 Outbreaks in Congregate Residential Settings: San Francisco’s Outbreak Response in Single-Room Occupancy Hotels Cohen SE, Stookey J, Anderson N, Morris D, Singzon T, Dann M, Burk K, Chen CC. Public Health Reports. 2023 Jan-Feb; 138(1): 7-13.
• Risky business: A mixed methods study of decision-making regarding COVID-19 risk at a US public university Facente SN, De Zuzuarregui M, Frank D, Gomez-Aladino S, Muñoz A, Williamson S, Wang E, Hunter L, Packel L, Reingold A, Petersen M. Frontiers in Psychology. 2022 Jul 29; 13: 926664.
• Acceptability and feasibility of leveraging community-based HIV counselling and testing platforms for same-day oral PrEP initiation among adolescent girls and young women in Eastern Cape, South Africa Medina-Marino A, Bezuidenhout D, Ngwepe P, Bezuidenhout C, Facente SN, Mabandla S, Hosek S, Little F, Celum CL, Bekker L-G. Journal of the International AIDS Society. 2022 Jul; 25(7): e25968.
• Anticipated and experienced stigma after testing positive for SARS-CoV-2: A qualitative study Facente SN, De Zuzuarregui M, Frank D, Gomez-Aladino S, Muñoz A, Williamson S, Wang E, Hunter L, Packel L, Reingold A. Health Promotion Practice. 2022 Aug 11 (online ahead of print).
• A cross-sectional study comparing men who have sex with men and inject drugs and people who inject drugs who are men and have sex with men in San Francisco: Implications for HIV and hepatitis C virus prevention Artenie A, Facente SN, Patel S, Stone J, Hecht J, Rhodes P, McFarland W, Wilson E, Vickerman P, Morris MD. Health Science Reports. 2022 Jul 12; 5(4): e704.
• Sexually transmitted infection screening to prevent adverse birth and newborn outcomes: study protocol for a randomized‑controlled hybrid‑effectiveness trial Medina-Marino A, Cleary S, Muzny CA, Taylor C, Tamhana A, Ngwepe P, Bezuidenhout C, Facente SN, Mlisana K, Peters RPH, Klausner JD. Trials. 2022; 23:441.
• Hepatitis C prevalence and key population size estimate updates in San Francisco: 2015 to 2019 Facente SN, Grinstein R, Bruhn R, Kaidarova Z, Wilson E, Hecht J, Burk K, Grebe E, Meghan MD. PLOS ONE. 2022; 17(5): e0267902.
• Hepatitis C Elimination During a Global Pandemic: A Case Study of Resilience in Action Facente SN, Grinstein R, Broussard J, Shost J, Azari S, Siruno J, Jimenez JA, Luetkemeyer AF, Burk K. Public Health Reports. 2022 May 11; 17(5): e0267902.
• Use of HIV Recency Assays for HIV Incidence Estimation and Other Surveillance Use Cases: Systematic Review Facente SN, Grebe E, Maher AD, Fox D, Scheer S, Mahy M, Dalal S, Lowrance D, Marsh K. JMIR Public Health Surveillance. 2022 Mar 11; 8(3): e34410.
• Factors Associated with Stigma Related to HIV Pre-Exposure Prophylaxis (PrEP) Use Among Men Who Have Sex With Men (MSM) Bhatta DN, Hecht J, Facente SN. Sexually Transmitted Infections. 2022 Feb 4: sextrans-2021-055296.
• Impact of Racial Categorization on Effect Estimates: An HIV Stigma Analysis Facente SN, Lam-Hine T, Bhatta DN, Hecht J. American Journal of Epidemiology. 2022 Mar 24; 191(4): 689-695.
• Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence Facente SN, Reiersen AM, Lenze EJ, Boulware DR, Klausner JD. Drugs. 2021 Dec; 81(18): 2081-2089.
• Are You Really the Doctor? Physician Experiences with Gendered Microaggressions from Patients Ahmad SR, Ahmad TR, Balasubramanian V, Facente S, Kin C, Girod S. Journal of Women’s Health. 2022 Apr; 31(4): 521-532. 
• Examining the impact of the Golden Compass clinical care program for older people with HIV: A qualitative study Tan JY, Greene M, Blat C, Albers A, Grochowski J, Oskarsson J, Shiels M, Hsue P, Havlir D, Gandhi M, Myers J. AIDS & Behavior. 2022 May; 26(5): 1562-1571.
• Hepatitis C Mortality Trends in San Francisco: Can we Reach Elimination Targets? Mirzazadeh A, Facente SN, Burk K, Kahn JG, Morris MD; End Hep C SF. Annals of Epidemiology. 2022 Jan; 65: 59-64.
• Feasibility and Effectiveness of Daily Temperature Screening to Detect COVID-19 in a Prospective Cohort at a Large Public University Facente SN, Hunter LA, Packel LJ, Li Y, Harte A, Nicolette G, McDevitt S, Petersen M, Reingold AL. BMC Public Health. 2021 Sep 16; 21(1): 1693.
• What Surgeons Want: Access to Online Surgical Education and Peer-to-Peer Counseling – a Qualitative Study Häberle AD, Nath R, Facente SN, Albers AE, Girod S. Craniomaxillofacial Trauma & Reconstruction. 2021 Sep; 14(3): 189-195.
• Hepatitis C Care Cascades for 3 Populations at High Risk: Low-income Trans Women, Young People Who Inject Drugs, and Men Who Have Sex With Men and Inject Drugs Facente SN, Patel S, Hecht J, Wilson E, McFarland W, Page K, Vickerman P, Fraser H, Burk K, Morris MD. Clinical Infectious Diseases. 2021 Sep 15; 73(6): e1290-e1295.
• Psychosocial Determinants of HIV Stigma Among Men Who Have Sex With Men in San Francisco, CA Bhatta DN, Hecht J, Facente SN. International Journal of Environmental Research and Public Health. 2021; 18(5): 8031.
• Progress toward closing gaps in the hepatitis C virus cascade of care for people who inject drugs in San Francisco Mirzazadeh A, Chen YH, Lin J, Burk K, Wilson EC, Miller D, Veloso D, McFarland W, Morris MD. PLOS ONE. 2021 Apr 2; 16(4):e0249585.
• Bovine Ownership and Reduced Pulmonary Tuberculosis Risk in Nepal: A Case–control Study Bates MN, Pope K, Sijali TR, Albers AE, Verma SC. Zoonoses Public Health. 2021; 00: 1-8.
• Piloting an Integrated SARS-CoV-2 Testing and Data System for Outbreak Containment among College Students: A Prospective Cohort Study Packel L, Reingold A, Hunter L, Facente SN, Li Y, Harte A, Nicolette G, Urnov FD, Lu M, Petersen M. PLOS ONE. 2021; 16(1): e0245765.
• Estimated Dates of Detectable Infection (EDDIs) as an Improvement upon Fiebig Staging for HIV Infection Dating Facente SN, Grebe E, Pilcher CD, Busch MP, Murphy G, Welte A. Epidemiology & Infection. 2020; 148: e53.
• Smoking-Cessation Interventions in Appalachia: A Systematic Review and Meta-Analysis Gupta S, Scheuter C, Kundu A, Bhat N, Cohen A, Facente SN. American Journal of Preventive Medicine. 2020; 58(2): 261-269.
• Interpreting HIV Diagnostic Histories into Infection Time Estimates: Analytical Framework and Online Tool Grebe E, Facente SN, Bingham J, Pilcher CD, Powrie A, Gerber J, Priede G, Chibawara T, Busch MP, Murphy G, Kassanjee R, Welte, A, and the Consortium for the Evaluation and Performance of HIV Incidence Assays (CEPHIA). BMC Infectious Diseases. 2019 Oct 26; 19(1): 894.
• Challenges to the Performance of Current HIV Diagnostic Assays and the Need for Centralized Specimen Archives: a Review of the Consortium for the Evaluation and Performance of HIV Incidence Assays (CEPHIA) Repository Facente SN, Busch MP, Grebe E, Pilcher CD, Welte A, Rice B, Murphy G. Gates Open Research. 2019 July 23; 3: 1511.
• Performance Comparison of the Maxim and Sedia Limiting Antigen Avidity Assays for Incidence Surveillance Sempa JB Welte A, Busch MP, Hall J, Hampton D, Keating SM, Facente SN, Marson K, Parkin N, Pilcher CD, Murphy G, Grebe E; Consortium for the Evaluation and Performance of HIV Incidence Assays (CEPHIA). PLOS ONE. July 26, 2019, 14(7): e0220345.
• Hepatitis C seroprevalence and engagement in related care and treatment among trans women Wilson EC, Turner C, Lin J, McFarland W, Burk K, Raymond HF. Journal of Viral Hepatitis. 2019 Jul; 26(7): 923-925. 
• Household Fuel Use and Latent Tuberculosis Infection in a Nepali Population Albers AE, Pope K, Sijali TR, Subramanya SH, Verma SC, Bates MC. Environmental Research. 2019 June; 173: 69-76.
• A Generalizable Method for Estimating Duration of HIV Infections Using Clinical Testing History and HIV Results Pilcher CD, Porco TC, Facente SN, Grebe E, Delaney KP, Masciotra S, Kassanjee R, Busch MP, Murphy G, Owen SW, Welte A; Consortium for the Evaluation and Performance of HIV Incidence Assays (CEPHIA). AIDS. 2019 June 1; 33(7): 1231-1240.
• The Genetic Interaction between HIV and the Antibody Repertoire Strauli N, Fryer EK, Pham O, Abdel-Mohsen M, Facente SN, Pilcher C, Pennings P, Pillai S, Hernandez RD. The genetic interaction between HIV and the antibody repertoire. bioRxiv. 2019 May 23. doi:10.1101/646968.
• New Treatments Have Changed the Game: Hepatitis C Treatment in Primary Care Facente SN, Burk K, Eagen K, Mara ES, Smith AA, Lynch CS. Infectious Disease Clinics of North America. 2018 June; 32(2): 313-322.
• Localized US Efforts to Eliminate Hepatitis C Gaudino A, Gay B, Garmon C, Selick M, Vreeland R, Burk K, Huriaux E, Facente SN, Luetkemeyer A, Waters P, Graham CS. Infectious Disease Clinics of North America. 2018 June; 32(2): 293-311.
• Estimated Hepatitis C Prevalence and Key Population Sizes in San Francisco: A Foundation for Elimination Facente SN, Grebe E, Burk K, Morris MD, Murphy E, Mirzazadeh A, Smith A, Sanchez M, Evans J, Nishimura A, Raymond HF. PLOS ONE. 2018 April 11; 13(4): e0195575.
• Computational Analysis of Antibody Dynamics Identifies Recent HIV-1 Infection Seaton KE, Vandergrift NA, Deal AW, Rountree W, Bainbridge J, Grebe E, Anderson DA, Sawant S, Shen X, Yates NL, Denny TN, Liao H-X, Haynes BF, Robb ML, Parkin N, Santon BR, Garrett N, Price MA, Naniche D, Duerr AC, Keating S, Hampton D, Facente S, Marson K, Welte A, Pilcher CD, Cohen MS, Tomaras GD. JCI Insight. 2017 December 22; 2(24): e94355.
• Infection Staging and Incidence Surveillance Applications of High Dynamic Range Diagnostic Immuno-Assay Platforms Grebe E, Welte A, Hall J, Keating SM, Facente SN, Marson K, Martin JN, Little SJ, Price MA, Kallas EG, Busch MP, Pilcher CD, Murphy G; Consortium for the Evaluation and Performance of HIV Incidence Assays (CEPHIA). Journal of Acquired Immune Deficiency Syndromes, 2017 December 15; 76(5): 547-555.
• HIV Antibody Level as a Marker of HIV Persistence and Low Level Viral Replication Keating SM, Pilcher CD, Jain V, Lebedeva M, Hampton D, Abdel-Mohsen M, Deng X, Murphy G, Welte A, Facente SN, Hecht F, Deeks SG, Pillai SK, Busch MP. Journal of Infectious Diseases. 2017; 216: 72–81.
• Comparison of Cross-sectional HIV Incidence Assay Results from Dried Blood Spots and Plasma Schlusser KE, Pilcher C, Kallas EG, Santos BR, Deeks SG, Facente S, Keating SM, Busch MP, Murphy G, Welte A, Quinn T, Eshleman SH, Laeyendecker O. PLOS ONE. 2017 February 23; 12(2): e0172283.
• Moving Towards a Reliable HIV Incidence Test – Current Status, Resources Available, Future Directions and Challenges Ahead Murphy G, Pilcher CD, Keating SM, Kassanjee R, Facente SN, Welte A, Grebe E, Marson K, Busch MP, Dailey P, Parkin N, Osborn J, Ongarello S, Marsh K, Garcia-Calleja JM; Consortium for the Evaluation and Performance of HIV Incidence Assays (CEPHIA), Foundation for Innovative New Diagnostics, UNAIDS, and the WHO Technical Working Group. Epidemiology & Infection, 2017 Apr, 145(5): 925-941.
• Performance of the Bio-Rad Geenius HIV-1/2 Supplemental Assay in Detecting ‘Recent’ HIV Infection and Calculating Population Incidence Keating SM, Kassanjee R, Lebedeva M, Facente SN, MacArthur JC, Grebe E, Murphy G, Welte A, Martin JN, Little S, Price MA, Kallas EG, Busch MP, Pilcher CD; Consortium for the Evaluation and Performance of HIV Incidence Assays (CEPHIA). Journal of Acquired Immune Deficiency Syndromes, 2016 December 15; 73(5): 581-588.
• Viral Load Criteria and Threshold Optimization to Improve HIV Incidence Assay Characteristics – a CEPHIA Analysis Kassanjee R, Pilcher CD, Busch MP, Murphy G, Facente SN, Keating SM, McKinney E, Marson K, Price MA, Martin JN, Little SJ, Hecht FM, Kallas EG, Welte A; Consortium for the Evaluation and Performance of HIV Incidence Assays (CEPHIA). AIDS. 2016; 30: 2361-2371.
• Using a Multitest Algorithm to Improve the Positive Predictive Value of Rapid HIV Testing and Linkage to HIV Care in Nonclinical HIV Test Sites Delaney KP, Rurangirwa J, Facente S, Dowling T, Janson M, Knoble T, Vu A, Hu YW, Kerndt PR, King J, Scheer S. Journal of Acquired Immune Deficiency Syndromes. 2016 Jan 1; 71(1): 78-86.
• Independent Assessment of Candidate HIV Incidence Assays on Specimens in the CEPHIA Repository Kassanjee R, Pilcher CD, Keating SM, Facente SN, McKinney E, Price MA, Martin JN, Little S, Hecht FM, Kallas EG, Welte A, Busch MP, and Murphy G. AIDS. 2014 October 23; 28(16): 2439-2449.
• Performance of Rapid Point-of-Care and Laboratory Tests for Acute and Established HIV Infection in San Francisco Pilcher CD, Louie B, Facente S, Keating S, Hackett J, Vallari A, Hall C, Dowling T, Busch MP, Klausner JD, Hecht FM, Liska S, Pandori MW. PLOS ONE, 2013 December; 8(12): e80629.
• Performance of Risk-Based Criteria for Targeting Acute HIV Screening in San Francisco Facente SN, Pilcher CD, Hartogensis WE, Klausner JD, Philip SS, Louie B, Christopoulos KA, Dowling T, and Colfax GN. PLOS ONE. 2011 July; 6(7): e21813.
• From Questionnaire to Conversation: A Structural Intervention to Improve HIV Test Counseling Sheon N, Lee S-H, and Facente SN. Patient Education and Counseling. 2010 December; 81(3): 468-475.
• False Positive Rate of Rapid Oral Fluid HIV Tests Increases as Kits Near Expiration Date Facente SN, Dowling T, Vittinghoff E, Sykes DL, and Colfax GN. PLOS ONE; 2009 December; 4(12): e8217.
• Addressing Food Security Through Public Policy Action in a Community-Based Participatory Research Partnership Breckwich-Vásquez V, Lanza D, Hennessey-Lavery S, Facente S, Halpin HA, Minkler M. Health Promotion Practice. 2007 October; 8(4): 342-349.
• Sowing the Seeds for Sustainable Change: A Community-Based Participatory Research Partnership for Health Promotion in Indiana, USA and its Aftermath Minkler M, Breckwich-Vásquez V, Rains-Warner J, Steussey H, Facente SN. Health Promotion International. 2006 December; 21(4): 293-300.
• Post-marketing Surveillance of OraQuick Whole Blood and Oral Fluid Rapid HIV Testing Wesolowski, LG, MacKellar DA, Facente SN, Dowling T, Ethridge SF, Zho JH, and Sullivan PS.  Post-Marketing Surveillance of OraQuick Whole-Blood and Oral-Fluid Rapid HIV Testing.  AIDS. 2006 August; 20(12): 1661-1666.